



## (51) International Patent Classification:

C07D 515/22 (2006.01) A61P 35/00 (2006.01)  
A61K 31/395 (2006.01)

## (21) International Application Number:

PCT/EP2017/059511

## (22) International Filing Date:

21 April 2017 (21.04.2017)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/326,156 22 April 2016 (22.04.2016) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85  
Södertälje (SE).

(72) Inventors: **HIRD, Alexander**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **BELMONTE, Matthew, Alan**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **YANG, Wenzhan**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **SECRIST, John, Paul**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **ROBBINS, Daniel, William**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **KAZMIRSKI, Steven, Lee**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **WU, Dedong**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **PENG, Bo**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **JOHANNES, Jeffrey**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **LAMB, Michelle, Laurae**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **YE, Oing**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). **ZHENG, Xiaolan**; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US).

(74) Agent: **NESS, Mark**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


## Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

## Published:

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

(54) Title: MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCER



(57) Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14.7.0.11.15.0.16.21.0.20.24.0.30.35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14.7.0.11.15.0.16.21.0.20.24.0.30.35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

From the INTERNATIONAL BUREAU

**PCT**NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

NESS, Mark  
Milstein Building Granta Park  
Cambridge Cambridgeshire CB21 6GH  
ROYAUME-UNI

|                                                                          |                                                                                 |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Date of mailing (day/month/year)<br><b>03 November 2017 (03.11.2017)</b> | <b>IMPORTANT NOTIFICATION</b>                                                   |
| Applicant's or agent's file reference<br><b>200407-WO-PCT</b>            |                                                                                 |
| International application No.<br><b>PCT/EP2017/059511</b>                | International filing date (day/month/year)<br><b>21 April 2017 (21.04.2017)</b> |

|                                                                                                                                             |                                                                               |                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------|
| 1. The following indications appeared on record concerning:                                                                                 |                                                                               |                                      |
| <input type="checkbox"/> the applicant                                                                                                      | <input checked="" type="checkbox"/> the inventor                              | <input type="checkbox"/> the agent   |
| <input type="checkbox"/> the common representative                                                                                          |                                                                               |                                      |
| Name and Address<br><b>YE, Qing</b><br><b>AstraZeneca 35 Gatehouse Drive</b><br><b>MA, Waltham 02451</b><br><b>United States of America</b> | State of Nationality                                                          | State of Residence                   |
|                                                                                                                                             | Telephone No.                                                                 |                                      |
|                                                                                                                                             | Facsimile No.                                                                 |                                      |
|                                                                                                                                             | E-mail address                                                                |                                      |
| 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:                           |                                                                               |                                      |
| <input type="checkbox"/> the person                                                                                                         | <input checked="" type="checkbox"/> the name                                  | <input type="checkbox"/> the address |
| <input type="checkbox"/> the nationality                                                                                                    |                                                                               |                                      |
| <input type="checkbox"/> the residence                                                                                                      |                                                                               |                                      |
| Name and Address<br><b>YE, Qing</b><br><b>AstraZeneca 35 Gatehouse Drive</b><br><b>MA, Waltham 02451</b><br><b>United States of America</b> | State of Nationality                                                          | State of Residence                   |
|                                                                                                                                             | Telephone No.                                                                 |                                      |
|                                                                                                                                             | Facsimile No.                                                                 |                                      |
|                                                                                                                                             | E-mail address<br><input type="checkbox"/> Notifications by e-mail authorized |                                      |
| 3. Further observations, if necessary:                                                                                                      |                                                                               |                                      |
| 4. A copy of this notification has been sent to:                                                                                            |                                                                               |                                      |
| <input checked="" type="checkbox"/> the receiving Office                                                                                    | <input type="checkbox"/> the International Preliminary Examining Authority    |                                      |
| <input checked="" type="checkbox"/> the International Searching Authority                                                                   | <input checked="" type="checkbox"/> the designated Offices concerned          |                                      |
| <input type="checkbox"/> the Authority(ies) specified for supplementary search                                                              | <input type="checkbox"/> the elected Offices concerned                        |                                      |
|                                                                                                                                             | <input type="checkbox"/> other:                                               |                                      |

|                                                                                               |                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| The International Bureau of WIPO<br>34, chemin des Colombettes<br>1211 Geneva 20, Switzerland | Authorized officer<br><br><b>Righetto Norbert</b><br>e-mail <a href="mailto:pct.team5@wipo.int">pct.team5@wipo.int</a><br>Telephone No. +41 22 338 74 05 |
| Facsimile No. +41 22 338 89 75                                                                |                                                                                                                                                          |